Abstract
Purpose :
To investigate the impact of preoperative injection of intravitreal conbercept (IVC) on the levels of 52 cytokines in the vitreous of eyes with proliferative diabeticretinopathy (PDR).
Methods :
This is a prospective, randomized, controlled study. A total of 87 patients with PDR were recruited to IVC-1 Day (n = 21), IVC-3 Day (n = 19), IVC-5 Day (n=23), and IVC-7 Day (n = 24), according to the day receiving IVC before vitrectomy. Twenty four PDR patients receiving no IVC treatment before vitrectomy were grouped as IVC-sham group. Besides, 20 eyes from 20 patients with macular hole (MH) or epiretinal membrane (ERM) served as the Control group. Vitreous samples were obtained at the time of vitrectomy from all eyes, and the concentration of 52 cytokines such as VEGF-A, VEGF-B, PIGF was measured using Cytokine-antibody array or ELISAs.
Results :
Among the 52 cytokines, VEGF-A, VEGF-B, Angiopoietin-2, CXCL12, endostatin, FGF, IL-18, MIF, MMP-1, MMP-3, MMP-7, PDGF-DD, PLGF, IL-1β, IL-2, IL-4, IL-9, IL-12, IL-13, IL-17A, G-CSF, IFN-g, FGF, IP-10, MCP-1, MIP-1a, PDGF-bb, MIP-1b, RANTES,TNF-a, TGF-b1, and TGF-b2 were increased significantly in the IVC-sham group compared to the Control group. In the IVC group, the mean levels (IVC/sham) of MMP-1 (207.33/305.37, P = 0.04), TGF-b2 (477.61/661.2, P<0.01) and CTGF (28.12/2282.19, P<0.01) were significantly lower when compared with those in the IVC-sham group. No significant difference was observed in the levels of TGF-b2 and CTGF between the IVC group and the Control group (TGF-b2p=0.11, CTGF p=0.97). In the subgroup analysis among groups of IVC-1 Day, IVC-3 Day, IVC-5 Day, and IVC-7 Day, we detected no difference of the concentration of the vitreous cytokines.
Conclusions :
Vitreous MMP-1, TGF-b2, and CTGF levels were up-regulated markedly in patients with PDR and decreased significantly after IVC treatment. No difference of the vitreous cytokine concentration was detected in patients receiving IVC on different day within one week prior to vitrectomy.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.